Human Igg News Today

Managing wrong blood transfusion to an RhD negative woman in labor. Click to read more...

This product profile describes the features and advantages of Lumit™ for immunoassay research.

A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.

Afucosylated monoclonal antibodies (mAb) have been shown to demonstrate an increased binding affinity. To this end, Sino Biological has established a process for afucosylated mAb expression that helps produce antibodies with higher therapeutic efficiency.

BA.2.75 is an emerging omicron variant that health organizations are becoming increasingly concerned about. ACROBiosystems discusses how they have produced a range of BA.2.75 antigen products in order to combat the variant of concern.

BA.2.75 is an emerging omicron variant that has been classed as a variant of interest by the WHO. ACROBiosystems has developed a huge range of antigen products, including Spike trimers and nucleocapsid proteins to help with research into the omicron variant.

In this article, ACROBiosystems discusses BA.2.75, a newly emerging SARS-CoV-2 variant with surprising transmission speed, and the potential ramifications this has against the ongoing fight against COVID-19.

In this article, ACROBiosystems discusses COVID-19, specifically omicron recombinants and how this could lead to new, infectious strains emerging.

In this article, ACROBiosystems demonstrates how DLL-3 could become a potential target for a variety of lung cancer therapies.

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, R...